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eespite the availability of multiple treatment options, chronic
schemic heart disease (IHD) and heart failure remain major
auses of morbidity and mortality. New therapeutic strate-
ies are currently being developed with the aim to reduce
schemic injury, replace damaged tissue, and improve post-
schemic cardiac function. In the past decade, high hopes
ere put on 2 such novel concepts, namely cell-based
herapy (1) and therapeutic angiogenesis (2). Both treat-
ents provided exciting results in animal models of IHD,
nd their therapeutic efficacies are currently being investi-
ated in clinical trials. However, although cell-based ther-
py in patients was safe and modestly improved left ven-
See page 1858
ricular ejection fraction in patients with acute myocardial
nfarction, its efficacy in reversing established heart failure
uring chronic IHD is less established (1). Another out-
tanding issue remains: which cells—bone marrow-derived
r tissue resident stem/progenitor cells—represent the high-
st potential for cardiac regeneration when transplanted or
nfused (1). Moreover, the concept of improving IHD by
herapeutic angiogenesis using clinical administration of
ngiogenic factors such as basic fibroblast growth factor
bFGF or FGF-2) has been poised with limited therapeutic
ffects, in part due to safety issues and difficulties in efficient
ormulation and/or delivery (2). Hence, we are forced to put
ore efforts at the bench and better characterize the mech-
nisms and effects of these new treatments, which might, in
urn, result in better translation at the bedside.
In this issue of the Journal, Takehara et al. (3) elegantly
tudied, in a porcine model of chronic IHD, the combined
ffects of therapeutic angiogenesis and cell-based therapy. In
first set of experiments, they randomized pigs with IHD
induced 1 month earlier via temporary coronary artery
cclusion) to receive an epicardial implantation of slow-
eleasing bFGF hydrogels, and tested the effect of bFGF on
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From †Leibniz AG, ‡Institute of Cardiovascular Regeneration, Centre for Mo-
ecular Medicine, University of Frankfurt, Frankfurt, Germany; and the §Vesaliusv
esearch Center, Flemish Institute of Biotechnology, University of Leuven, Leuven,
elgium.yocardial revascularization and contractile function (eval-
ated by clinically relevant methods). At 4 weeks after
mplantation, local sustained bFGF therapy had stimulated
yocardial perfusion by the enhanced formation of arte-
ioles in the infarct and border zone, yet one has to note that
he effects were not critically compared with a control group
ith empty hydrogels. Nevertheless, these positive effects
fter bFGF therapy were associated with higher left ven-
ricular ejection fraction of the ischemic heart, though it
emains unclear whether the infarct size was reduced. Thus,
onsistent with earlier studies by others (2), local sustained
FGF therapy efficiently stimulated the revascularization of
hronically ischemic pig hearts.
In a second set of experiments (3), the investigators again
andomized chronically ischemic pigs but now combined
ocal bFGF therapy with intramyocardial injection of hu-
an cardiosphere-derived cells (hCDCs), which are re-
arded as putative cardiac stem cells (4). Compared with
FGF therapy alone, cotransplantation of hCDCs strongly
mplified the positive effects of bFGF therapy on infarct
ize, left ventricular ejection fraction, and regional wall
otion at 4 weeks after treatment. Further genetic labeling
xperiments revealed that bFGF therapy stimulated the
ardiac differentiation and fusion of hCDCs in vivo, sug-
esting that at least part of the additive effects of this
ombined growth factor/cell-based strategy might be related
o improved cardiac regeneration.
Notably, the concept of combining growth factor and
ell-based therapy is not novel. Indeed, previous studies
lready identified the beneficial effects of applying pro-
ngiogenic growth factors (e.g., vascular endothelial growth
actor or stromal-derived factor-1) to enhance the efficacy of
ell-based therapy (for review, see Dimmeler and Leri [5])
nd that prolonged delivery of antiapoptotic growth factors
uch as insulin-like growth factor-1 by means of biotinyl-
ted nanofibers improved left ventricular function after
yocardial infarction in rodents, demonstrating that mod-
lation of the local cellular microenvironment can improve
ell therapy (6). Still, the current results by Takehara et al.
3) might provide some interesting new insights. Given the
bservation of stronger revascularization of the ischemic
yocardium, it is conceivable that local bFGF therapy
nhanced the efficacy of hCDC transplantation indirectly
ia providing an attractive microenvironment, highly per-
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December 2, 2008:1866–8 Better Regenerative Output After Cellular Inputissive for donor cell engraftment, survival, and integration
a “cardiogenic niche”) (Fig. 1). Indeed, by using magnetic
esonance imaging-based in vivo cell tracking, the investi-
ators observed, compared with hCDCs alone, a stronger
ngraftment of hCDCs after bFGF therapy in chronically
schemic hearts at 4 weeks after injection (3). This effect was
unctionally relevant as it was associated with smaller infarcts
nd higher left ventricular ejection fraction.
However, Takehara et al. (3) also present results that may
uggest some direct beneficial effects of bFGF on the trans-
lanted hCDCs. Indeed, bFGF stimulated the activation of
arious signaling pathways in hCDCs in vitro, including Akt
3). As Akt was previously shown (7) to be critical for survival
f transplanted cells in the ischemic heart, one might speculate
hat bFGF directly supported the survival (and subsequent
ngraftment) of injected hCDCs. However, because the inves-
igators did not dissect the underlying mechanisms, it is
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Figure 1 Proposed Concept of
Combined bFGF and Cell-Based Therapy
In part by enhancing myocardial revascularization, but perhaps also via direct
effects, local basic fibroblast growth factor (bFGF) therapy promotes the forma-
tion of cardiogenic niches in the chronically ischemic heart, and these niches
augment the engraftment and cardiac commitment (via bona fide differentiation
as well as cell fusion) of transplanted cells such as human cardiosphere-de-
rived cells. As a result, cardiac regeneration is stimulated, contractile dysfunc-
tion is ameliorated, and established heart failure might be reversed.mpossible to discriminate between a direct effect of bFGF on apoptosis and indirect effects on cell survival by improved
xygen supply to the tissue.
Another direct effect of bFGF might be the enhanced
ommitment of hCDCs to mature cardiomyocytes via in-
reased cell fusion but, importantly, also independently of cell
usion via enhanced bona fide cardiac differentiation (3) (Fig. 1).
his might have been unexpected given the notion that, unlike
broblast growth factor 8b and members of the Wnt, bone
orphogenetic protein/transforming growth factor, and Notch
athway (8), bFGF is not considered as a standard stimulator
f cardiac differentiation. Yet, bFGF was previously shown (9)
o control the differentiation of resident cardiac precursor cells;
he underlying mechanisms remain, however, an outstanding
ssue. Takehara et al. (3) did, unfortunately, not show the in
ivo functional integration and electrical coupling of hCDC-
erived cardiomyocytes beyond any doubt.
Another important finding by Takehara et al. (3) is the
herapeutic effect of hCDC injection in a large animal
odel of IHD. These data nicely corroborate earlier obser-
ations with hCDCs in rodent models of acute IHD (4),
ut are also the first to evidence the therapeutic efficacy of
uman cardiac stem cell transplantation in a model of
hronic IHD. Further investigations are warranted to iden-
ify the potential of hCDCs in clinical cell-based therapy.
One aspect of the study by Takehara et al. (3) focused on
omparing the therapeutic efficacy of injecting hCDCs
ersus human bone marrow-derived mesenchymal stem cells
hMSCs) in bFGF-treated ischemic pigs. As the investiga-
ors found that, in contrast to hCDCs, cotransplantation of
MSCs failed to convey extra effects on infarct size or
unctional recovery beyond those obtained by bFGF therapy
lone, their results suggested the superiority of using hC-
Cs over hMSCs in the context of cell-based therapy.
hese data were corroborated by findings that bFGF
herapy failed to stimulate cardiac differentiation of hMSCs
n vivo. It remains unclear why the investigators found, in
ontrast to many others (1), little benefit of hMSCs, but one
ight speculate that it had to do with technical disparities
n culturing and expansion (e.g., the investigators added
FGF to the culture), and the use of frozen cells, which had
o be thawed before application, potentially resulting in
nferior engraftment and survival.
A last important insight situates around the application of
iodegradable hydrogels for sustained release of recombi-
ant proteins (3). As these hydrogels lasted only up to 3
eeks in vivo (3), they are suitable for clinical application.
esides creating a cardiogenic niche for transplanted cells,
his form of sustained drug delivery might also revive the
eld of therapeutic angiogenesis (2).
In summary, Takehara et al. (3) provide compelling evi-
ence in a large animal model that the functional recovery of
hronically ischemic hearts via cell-based therapy is improved
y sustained local release of bFGF, at least in part via
romoting transplant engraftment and cardiac regeneration.
ith their slow-release hydrogels, the investigators now have
powerful platform to test the efficacy to augment cell-based
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Better Regenerative Output After Cellular Input December 2, 2008:1866–8herapy of alternative angiogenic factors—such as vascular
ndothelial- placental-, and platelet-derived growth factors—
nd perhaps even of growth factor cocktails including other
ardioprotective cytokines such as insulin-like growth factor-1,
epatocyte growth factor, and granulocyte colony-stimulating
actor. Conversely, because of the enhanced engraftment of
ransplants, the investigators are in a privileged position to
arefully dissect the cardio-regenerative potential of various
andidate (stem) cell types (1). In any case, it will be important
o determine, following combined therapy, the long-term fate
f transplanted cells as well as the sustained improvement of
ardiac function leading to reduced morbidity and mortality
ver time.
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